Profiel
Alain Bernard is currently the Chief Technology Officer at VectivBio Holding AG since 2019.
Prior to this, he worked as the Head-Global Biotech Process Development at R-Pharm JSC from 2017 to 2019, Vice President-Biopharmaceutical Process Sciences at UCB SA from 2006 to 2016, and Director-Biotech Process Development at Merck Serono SA from 2002 to 2006.
Dr. Bernard holds a doctorate degree from the Massachusetts Institute of Technology.
Eerdere bekende functies van Alain Bernard
| Bedrijven | Functie | Einde |
|---|---|---|
R-Pharm JSC
R-Pharm JSC BiotechnologyHealth Technology Engages in research, development and manufacturing of medicines & wholesales medical supplies | Corporate Officer/Principal | 01-07-2019 |
| UCB | Corporate Officer/Principal | 01-01-2016 |
Merck Serono SA
Merck Serono SA Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops drugs for reproductive and metabolism | Corporate Officer/Principal | 01-11-2006 |
| VECTIVBIO HOLDING AG | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Alain Bernard
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 5 |
|---|---|
UCB SA
UCB SA Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceutical products | Health Technology |
Massachusetts Institute of Technology
Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
Merck Serono SA
Merck Serono SA Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops drugs for reproductive and metabolism | Health Technology |
R-Pharm JSC
R-Pharm JSC BiotechnologyHealth Technology Engages in research, development and manufacturing of medicines & wholesales medical supplies | Health Technology |
VectivBio Holding AG
VectivBio Holding AG Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics for rare diseases | Health Technology |
















